Canna~Fangled Abstracts

Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma

By July 29, 2021No Comments

. 2021 Jul 29.

doi: 10.1007/s00418-021-02018-4.

Online ahead of print.
Thangesweran Ayakannu123, Anthony H Taylor45, Justin C Konje36
Affiliations 

Abstract

Although the expression of the putative cannabinoid receptor GPR55 has been shown to be involved in the growth of various tumours and is increased in a number of cancers, its expression has not been examined in patients with endometrial cancer (EC). Quantitative RT-PCR (for mRNA levels) and immunohistochemistry (for protein levels) were used to measure GPR55 expression in patients with Type 1 and Type 2 EC and correlated against cannabinoid receptor (CB1 and CB2) protein levels using non-cancerous endometrium as the control tissue. The data indicated that GPR55 transcript and GPR55 protein levels were significantly (p < 0.002 and p < 0.0001, respectively) higher in EC tissues than in control tissues. The levels of immunoreactive GPR55 protein were correlated with GPR55 transcript levels, but not with the expression of CB1 receptor protein, and were inversely correlated with CB2 protein expression, which was significantly decreased. It can be concluded that GPR55 expression is elevated in women with EC, and thus could provide a potential novel biomarker and therapeutic target for this disease.

 

Keywords: Cannabinoid receptors, Endometrial cancer, GPR55, Gene expression, Immunohistochemistry, N-Acylethanolamine

References

    1. Alhouayek M, Masquelier J, Muccioli GG (2018) Lysophosphatidylinositols, from cell membrane constituents to GPR55 ligands. Trends Pharmacol Sci 39:586–604 – PubMed – DOI
    1. Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, Guzman M, Sanchez C (2011) The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene 30:245–252 – PubMed – DOI
    1. Andradas C, Caffarel MM, Pérez-Gómez E, Guzmán M, Sánchez C (2013) The role of GPR55 in cancer. In: Abood M, Sorensen R, Stella N (eds) endoCANNABINOIDS. Springer, New York
    1. Arifin SA, Falasca M (2016) Lysophosphatidylinositol signalling and metabolic diseases. Metabolites 6:6 – PMC – DOI – PubMed
    1. Ayakannu T, Taylor AH, Marczylo TH, Willets JM, Konje JC (2013) The endocannabinoid system and sex steroid hormone-dependent cancers. Int J Endocrinol 2013:259676 – PubMed – PMC – DOI

Leave a Reply